Novel Biomarker Approaches for Managing Patients With Cardiac Transplantation.
Despite major advances in the medical care of patients following heart transplantation (HTx) and a steady increase in long-term survival, allograft surveillance is still based on endomyocardial biopsy, the gold standard since the 1970s. This invasive procedure calls for less burdening and more cost-effective approaches. In recent years, impressive progress has been made in utilizing blood-based biomarkers for the diagnosis and management of diseases in a variety of fields. Hence, a number of trials have been performed testing the usefulness of circulating molecules or other technical methods to overcome the need for surveillance myocardial biopsy in HTx patients. Here, we review current approaches and the state of research on novel biomarkers for the management of patients following heart transplantation.
Division of Cardiology, Department of Medicine, Columbia University Medical Center, 622 West 168th Street, PH 10, Room 203, New York, NY, 10032, USA.
Peter J
PJ
Kennel
Division of Cardiology, Department of Medicine, Columbia University Medical Center, 622 West 168th Street, PH 10, Room 203, New York, NY, 10032, USA. pcs2121@cumc.columbia.edu.
P Christian
PC
Schulze
D015415:Biomarkers / Q000097:blood*; D001798:Blood Proteins / Q000378:metabolism; D004247:DNA / Q000097:blood; D006084:Graft Rejection / Q000175:diagnosis; D016027:Heart Transplantation; D006801:Humans; D020097:Natriuretic Peptide, Brain / Q000097:blood; D011182:Postoperative Care / Q000379:methods*; D012313:RNA / Q000097:blood; D014336:Troponin / Q000097:blood
D015415:Biomarkers; D001798:Blood Proteins; D014336:Troponin; D020097:Natriuretic Peptide, Brain; D012313:RNA; D004247:DNA
Biomarker; Heart transplantation; MicroRNA; Rejection; Survival; Transplantation biology